Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. more
Time Frame | VRDN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.24% | -2.06% | -0.55% |
1-Month Return | -6.93% | -1.92% | 2.72% |
3-Month Return | -10.11% | -10.4% | 7.66% |
6-Month Return | 55.42% | -4.6% | 10.15% |
1-Year Return | -10.07% | 4.06% | 27.53% |
3-Year Return | -4.87% | 1.94% | 32.31% |
5-Year Return | 158.61% | 36.48% | 89.2% |
10-Year Return | -96.63% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.46M | 1.05M | 2.96M | 1.77M | 314.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":23.54,"profit":true},{"date":"2021-12-31","value":66.42,"profit":true},{"date":"2022-12-31","value":39.72,"profit":true},{"date":"2023-12-31","value":7.04,"profit":true}] |
Cost of Revenue | 32.79M | 28.30M | 620.00K | 755.00K | 1.32M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":86.31,"profit":true},{"date":"2021-12-31","value":1.89,"profit":true},{"date":"2022-12-31","value":2.3,"profit":true},{"date":"2023-12-31","value":4.03,"profit":true}] |
Gross Profit | (28.33M) | (27.25M) | 2.34M | 1.02M | (1.01M) | [{"date":"2019-12-31","value":-1209.26,"profit":false},{"date":"2020-12-31","value":-1163.21,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":43.41,"profit":true},{"date":"2023-12-31","value":-43.02,"profit":false}] |
Gross Margin | (635.13%) | (2595.62%) | 79.08% | 57.39% | (321.02%) | [{"date":"2019-12-31","value":-803.19,"profit":false},{"date":"2020-12-31","value":-3282.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.58,"profit":true},{"date":"2023-12-31","value":-405.97,"profit":false}] |
Operating Expenses | 46.44M | 41.57M | 82.69M | 136.08M | 254.76M | [{"date":"2019-12-31","value":18.23,"profit":true},{"date":"2020-12-31","value":16.32,"profit":true},{"date":"2021-12-31","value":32.46,"profit":true},{"date":"2022-12-31","value":53.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (41.98M) | (110.38M) | (79.73M) | (134.30M) | (254.45M) | [{"date":"2019-12-31","value":-4197900000,"profit":false},{"date":"2020-12-31","value":-11038000000,"profit":false},{"date":"2021-12-31","value":-7972800000,"profit":false},{"date":"2022-12-31","value":-13430400000,"profit":false},{"date":"2023-12-31","value":-25445000000,"profit":false}] |
Total Non-Operating Income/Expense | 212.00K | (670.00K) | 630.00K | 8.86M | 32.09M | [{"date":"2019-12-31","value":0.66,"profit":true},{"date":"2020-12-31","value":-2.09,"profit":false},{"date":"2021-12-31","value":1.96,"profit":true},{"date":"2022-12-31","value":27.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (41.87M) | (110.72M) | (79.41M) | (129.87M) | (237.73M) | [{"date":"2019-12-31","value":-4187300000,"profit":false},{"date":"2020-12-31","value":-11071500000,"profit":false},{"date":"2021-12-31","value":-7941300000,"profit":false},{"date":"2022-12-31","value":-12987400000,"profit":false},{"date":"2023-12-31","value":-23773400000,"profit":false}] |
Income Taxes | 547.00K | 269.00K | 3.00K | (4.43M) | 18.56M | [{"date":"2019-12-31","value":2.95,"profit":true},{"date":"2020-12-31","value":1.45,"profit":true},{"date":"2021-12-31","value":0.02,"profit":true},{"date":"2022-12-31","value":-23.86,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (42.42M) | (110.98M) | (79.42M) | (125.44M) | (256.30M) | [{"date":"2019-12-31","value":-4242000000,"profit":false},{"date":"2020-12-31","value":-11098400000,"profit":false},{"date":"2021-12-31","value":-7941600000,"profit":false},{"date":"2022-12-31","value":-12544400000,"profit":false},{"date":"2023-12-31","value":-25629700000,"profit":false}] |
Income From Continuous Operations | (41.87M) | (110.72M) | (79.56M) | (130.11M) | (216.66M) | [{"date":"2019-12-31","value":-4187300000,"profit":false},{"date":"2020-12-31","value":-11071500000,"profit":false},{"date":"2021-12-31","value":-7956200000,"profit":false},{"date":"2022-12-31","value":-13010700000,"profit":false},{"date":"2023-12-31","value":-21665900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (42.42M) | (110.98M) | (79.42M) | (125.44M) | (237.73M) | [{"date":"2019-12-31","value":-4242000000,"profit":false},{"date":"2020-12-31","value":-11098400000,"profit":false},{"date":"2021-12-31","value":-7941600000,"profit":false},{"date":"2022-12-31","value":-12544400000,"profit":false},{"date":"2023-12-31","value":-23773400000,"profit":false}] |
EPS (Diluted) | (20.10) | (11.31) | (7.69) | (4.03) | (5.32) | [{"date":"2019-12-31","value":-2010,"profit":false},{"date":"2020-12-31","value":-1131,"profit":false},{"date":"2021-12-31","value":-769,"profit":false},{"date":"2022-12-31","value":-403,"profit":false},{"date":"2023-12-31","value":-532,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VRDN | |
---|---|
Cash Ratio | 18.21 |
Current Ratio | 18.55 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VRDN | |
---|---|
ROA (LTM) | -32.15% |
ROE (LTM) | -51.88% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VRDN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VRDN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5649.81 |
P/B | 3.29 |
Price/FCF | NM |
EV/R | 3850.99 |
EV/Ebitda | NM |
Viridian Therapeutics Inc (VRDN) share price today is $19.38
Yes, Indians can buy shares of Viridian Therapeutics Inc (VRDN) on Vested. To buy Viridian Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRDN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Viridian Therapeutics Inc (VRDN) via the Vested app. You can start investing in Viridian Therapeutics Inc (VRDN) with a minimum investment of $1.
You can invest in shares of Viridian Therapeutics Inc (VRDN) via Vested in three simple steps:
The 52-week high price of Viridian Therapeutics Inc (VRDN) is $27.2. The 52-week low price of Viridian Therapeutics Inc (VRDN) is $11.4.
The price-to-earnings (P/E) ratio of Viridian Therapeutics Inc (VRDN) is
The price-to-book (P/B) ratio of Viridian Therapeutics Inc (VRDN) is 3.29
The dividend yield of Viridian Therapeutics Inc (VRDN) is 0.00%
The market capitalization of Viridian Therapeutics Inc (VRDN) is $1.71B
The stock symbol (or ticker) of Viridian Therapeutics Inc is VRDN